Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects ; volume:36 ; number:2 ; day:23 ; month:11 ; year:2015 ; pages:127-136 ; date:2.2016
Clinical drug investigation ; 36, Heft 2 (23.11.2015), 127-136, 2.2016
- Urheber
-
Parasrampuria, Dolly A.
Weilert, Doris
Maa, Jen-Fue
Dishy, Victor
Kochan, Jarema
Shi, Minggao
Brown, Karen S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-015-0357-8
- URN
-
urn:nbn:de:101:1-2019063020570145891752
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Parasrampuria, Dolly A.
- Weilert, Doris
- Maa, Jen-Fue
- Dishy, Victor
- Kochan, Jarema
- Shi, Minggao
- Brown, Karen S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study
Der Einfluss von Dabigatran und Rivaroxaban auf die Thrombozytenfunktion
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care- sowie Plättchenfunktionstests
Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study
Der Einfluss von Dabigatran und Rivaroxaban auf die Thrombozytenfunktion
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care- sowie Plättchenfunktionstests
Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study
Der Einfluss von Dabigatran und Rivaroxaban auf die Thrombozytenfunktion
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care- sowie Plättchenfunktionstests
Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography